Welcome to our dedicated page for EHAVE ORD news (Ticker: EHVVF), a resource for investors and traders seeking the latest updates and insights on EHAVE ORD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect EHAVE ORD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of EHAVE ORD's position in the market.
Ehave, Inc. (OTC Pink: EHVVF) has appointed Dr. Jeffrey D. Kamlet as its new Chief Medical Officer, bringing over 30 years of experience in internal medicine and addiction. This strategic hire aims to deepen clinical expertise and advance clinical studies on I.V. Ketamine treatments targeting anxiety, depression, and PTSD. Dr. Kamlet, recognized for his work in ibogaine treatment and cardiac safety, expressed enthusiasm for joining Ehave's mission to enhance mental health treatment options. Ehave continues to focus on innovative therapeutics in the mental health sector.
Ehave, Inc. (EHVVF) introduces its Medical and Vaccine Passport aimed at streamlining Covid-19 vaccination verification for small businesses. This tool enables individuals to securely manage health records and vaccination status, providing convenience as mask mandates relax. With over 150 million potential users, the upcoming Ehave Mobile App will facilitate access to electronic health records (EHRs) and billing data. The app aims to empower users to combine their health data from various sources, supporting patient-generated data to enhance healthcare engagement.
Ehave, Inc. (EHVVF) announces a licensing agreement with Health Wizz to enhance its digital health dashboard by integrating medical records management capabilities. This partnership will enable users to securely share their personal health data while ensuring HIPAA compliance. The Health Wizz mobile app, coupled with blockchain technology, aims to empower individuals to manage their health data efficiently. The global market for Electronic Health Records (EHR) is projected to reach $33.41 billion by 2025, highlighting the significance of this advancement in patient care.
Ehave, Inc. (EHVVF) has launched its KetaDASH subsidiary, introducing a HIPAA-compliant platform for at-home ketamine treatments for anxiety, depression, and PTSD.
The service aims to facilitate access to IV ketamine therapy through partnerships with clinics and healthcare providers. With studies showing that up to 85% of ketamine users experience mental health improvements, this initiative addresses the growing demand for alternative mental health solutions.
CEO Ben Kaplan emphasized the importance of providing compassionate care in a home setting.
Ehave, Inc. (EHVVF) announced the upcoming launch of KetaDASH, a groundbreaking intravenous home delivery service for ketamine therapy, expected to begin by the end of Q2 2021. This platform enables licensed clinics to treat homebound patients, potentially increasing revenue opportunities. The company has secured liability coverage and is negotiating franchising across the U.S.
Ketamine, used for pain relief, is also being studied for depression treatment. KetaDASH offers a personalized approach, connecting patients with skilled nurses for at-home care.
Ehave, Inc. (EHVVF) announced a partnership with Brain Scientific Inc. to conduct brain mapping ketamine clinical trials aimed at treating chronic pain, depression, PTSD, and other mental disorders. The trial will enroll 35 patients and start in the second half of 2021, focusing on establishing a correlation between ketamine treatment and patient improvements. Ehave aims to leverage data and AI for better mental health solutions. The trial’s primary goal is to assess safety and tolerability, with updates promised throughout the clinical process.
Ehave, Inc. (EHVVF) is collaborating with Silo Wellness Inc. for a clinical study on the effects of psilocybin during wellness retreats in Jamaica. This study aims to explore the neurobiological impacts of psychedelic substances on mental health disorders such as depression, anxiety, and ADHD. Utilizing advanced EEG technologies, including Brain Scientific's NeuroCap, Ehave will collect data on brain activity before, during, and after psilocybin administration. This partnership highlights Ehave's commitment to enhancing therapeutic approaches through data-driven insights.
Ehave, Inc. (EHVVF), a provider of digital therapeutics in the psychedelic and mental health sectors, announced that its CEO, Benjamin Kaplan, will appear on the Psychedelic Spotlight segment of New to the Street. The segment will air on NewsMax on March 14th at 10:00 AM EST and on Fox Business on March 15th at 7:30 PM EST. This appearance is an opportunity for shareholders to gain insight into Ehave and the psychedelic sector. Ehave focuses on improving care for brain disorders through innovations like the Ehave Telemetry Portal.
Ehave, Inc. (OTC Pink: EHVVF) has filed a trademark application for its KetaDASH brand with the USPTO, accepted on February 26, 2021. This move aims to protect its brand as the company prepares for beta trials of its ketamine IV therapy in Q2 2021, utilizing advanced vein technology. Ehave has also filed to uplist to the OTCQB. KetaDASH provides a platform for patients to receive supervised ketamine treatment at home, connecting them with skilled nurses.
Ehave, Inc. (EHVVF) has announced plans to launch a beta trial of its innovative KetaDASH ketamine IV therapy in Q2 2021. This platform connects patients with skilled nurses to provide ketamine therapy at home, enhancing patient accessibility and comfort. Ehave has secured liability insurance for its services, eliminating additional costs for clinics. The partnership with Vein-Eye Carry aims to improve IV access success rates, which can fail in up to 40% of critically ill patients. CEO Ben Kaplan emphasizes the urgent need for effective mental health treatments, positioning KetaDASH as a significant advancement.
FAQ
What is the market cap of EHAVE ORD (EHVVF)?
